In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis | Zendy

Jian Xu | Zendy; Bin Wang | Zendy; Lei Fu | Zendy; Hui Zhu | Zendy; Shaochen Guo | Zendy; Haihong Huang | Zendy; Dali Yin | Zendy; Ye Zhang | Zendy; Yu Lu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis

Author(s) -

Jian Xu,

Bin Wang,

Lei Fu,

Hui Zhu,

Shaochen Guo,

Haihong Huang,

Dali Yin,

Ye Zhang,

Yu Lu

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02155-18

Subject(s) - clofazimine , tuberculosis , regimen , mycobacterium tuberculosis , bedaquiline , in vivo , pharmacology , isoniazid , medicine , first line , microbiology and biotechnology , immunology , biology , leprosy , pathology

The riminophenazine agent clofazimine (CFZ) is repurposed as an important component of the new short-course multidrug-resistant tuberculosis regimen and significantly shortens first-line regimen for drug-susceptible tuberculosis in mice. However, CFZ use is hampered by its unwelcome skin discoloration in patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research